Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Emerging Microbes & Infections|November 24, 2020
Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidateXiao-Yu Zhang, Jing Guo, Xin Wan, et al.
Cell Discovery|July 28, 2021
Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display librariesYongbing Pan, Jianhui Du, Jia Liu, et al.
Cell Discovery|April 7, 2021
Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronavirusesJianhui Nie, Qianqian Li, Li Zhang, et al.
Cell Discovery|September 8, 2022
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineagesXiaoman Li, Yongbing Pan, Qiangling Yin, et al.
Nature Immunology|January 5, 2024
Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virusHan Wang, Peng Yin, Tingting Zheng, et al.
Journal of Translational Internal Medicine|May 23, 2024
Impact of the Alberta Stroke Program CT Score subregions on long-term functional outcomes in acute ischemic stroke: Results from two multicenter studies in ChinaXinrui Wang, Caohui Duan, Jinhao Lyu, et al.
Eclinicalmedicine|August 4, 2022
Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trialYeqing Tong, Xinyue Zhang, Jinhua Chen, et al.
JAMA|August 14, 2020
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical TrialsShengli Xia, Kai Duan, Yuntao Zhang, et al.
Nature Communications|July 7, 2021
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in WuhanCesheng Li, Ding Yu, Xiao Wu, et al.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
Pageof 11